ArticleHepatology communications2026
Epigenetic drug control of Clec4g/LSECtin expression reduces fibrosis burden in cirrhosis.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver and lymph node endothelial cell C-type lectin (LSECtin) loss in liver sinusoidal endothelial cells (LSECs) during cirrhosis favors hepatic pro-inflammatory T-cell infiltration. We characterize histone protein post-translational modifications and DNA methylation in LSECs that may control LSECtin expression and evaluate methyltransferase inhibitors' capacity to retrieve LSECtin.
methodsDNA-methylation levels and histone post-translational modifications were studied by methylation array and ChIP-Seq experiments carried out on LSECs isolated by FACS from control and cirrhotic mice. Immortalized LSECs were treated with epigenetic effector inhibitory drugs (OTS186935-Suv39h2i, UNC0642-G9a/Glpi, UNC1999-EZH2/1i, 5-Aza-2'-deoxycitidine-DNMTi), alone and with IL-4, an LSECtin expression inducer. Drugs with regulatory potential were tested in vivo. LSECtin gene and protein expression, lymphocyte differentiation, and Th17-subpopulation proliferation were studied.
resultsH3K9me3 and H3K27Me3 were reduced in LSECs of cirrhotic versus control mice. Suv39h2 and Ezh2/1 methyltransferase inhibitors OTS186935 and UNC1999, respectively, reduced Clec4g/LSECtin expression in immortalized LSECs. Murine primary LSECs showed H3K27me3 and H3K9me3 significantly enriched (controls) and reduced (cirrhotics) regions located upstream of the Clec4g promoter. OTS186935 and UNC1999 treated immortalized LSECs reduced H3K9me3 and H3K27me3 enrichment in these regions. Clec4g/LSECtin expression was also controlled by DNA methylation, as confirmed by Clec4g/LSECtin induction after 5-Aza-2'-deoxycitidine-DNMTi treatment in vitro and in vivo. Epigenetic drugs induced LSECtin in LSECs, contracted the hepatic Th17 compartment, attenuated hepatic structural damage, and improved liver function in cirrhosis.
conclusionH3K9me3 and H3K27me3, and DNA-methylation regulate Clec4g expression in LSECs during cirrhosis. Inhibitory epigenetic-enzyme drugs increase Clec4g/LSECtin expression and provide evidence on relevant genomic regions for Clec4g reprogramming. The LSECtin-modulated hepatic Th17 compartment is contracted in cirrhosis by targeting these modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.